Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9801277 | 0.98 | SLC6A4 (0.32) | SLC6A4SLC6A2SLC6A3CHRM5CHRM3 | |
| SCHEMBL9801549 | 0.86 | SIGMAR1 (0.31) | SLC6A4SLC6A2SLC6A3CHRM5CHRM3 | |
| SCHEMBL27094636 | 0.82 | — | — | |
| SCHEMBL2385429 | 0.82 | — | — | |
| SCHEMBL10305702 | 0.80 | MEN1 (0.33) | SLC6A4SLC6A2SLC6A3CHRM5CHRM3 | |
| SCHEMBL17916212 | 0.78 | OPRL1 (0.40) | SLC6A4SLC6A2SLC6A3CHRM5CHRM3 | |
| SCHEMBL18855182 | 0.78 | CHRM5 (0.36) | SLC6A4SLC6A2SLC6A3CHRM5CHRM3 | |
| SCHEMBL3822012 | 0.78 | SIGMAR1 (0.36) | SLC6A4SLC6A2SLC6A3CHRM5CHRM3 | |
| SCHEMBL3914623 | 0.78 | GABBR2 (0.34) | MEN1KMT2AGABBR2GABBR1CYP2D6 | |
| SCHEMBL28806945 | 0.78 | SLC6A4 (0.30) | SLC6A4SLC6A2SLC6A3CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103351457-A | Hydroxyalkylated polyalkylene polyamine composition, method for producing the same and method for producing polyurethane resin using the same | TOSOH CORP | 2013-10-16 | — | — | CN | claimed |
| CN-101048366-A | Hydroxyalkylated polyalkylenepolyamine composition, method for producing same, and method for producing polyurethane resin using same | TOSOH CORP (JP) | 2007-10-03 | — | — | CN | claimed |
| CN-103351457-A | Hydroxyalkylated polyalkylene polyamine composition, method for producing the same and method for producing polyurethane resin using the same | TOSOH CORP | 2013-10-16 | — | — | CN | disclosed |
| US-8222311-B2 | Hydroxyalkylated polyalkylenepolyamine composition, method of producing the same and their use in polyurethanes | TOSOH CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20080004362-A1 | Hydroxyalkylated Polyalkylenepolyamine Composition, Method for Producing Same and Method for Producing Polyurethane Resin Using Such Hydroxyalkylated Polyalkylenepolyamine Composition | TOSOCH CORPORATION (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-101048366-A | Hydroxyalkylated polyalkylenepolyamine composition, method for producing same, and method for producing polyurethane resin using same | TOSOH CORP (JP) | 2007-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004362-A1 | Hydroxyalkylated Polyalkylenepolyamine Composition, Method for Producing Same and Method for Producing Polyurethane Resin Using Such Hydroxyalkylated Polyalkylenepolyamine Composition | SRM, HRH3, HNMT | SLC6A4 3878/4885SLC6A2 2919/4885SLC6A3 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.